PRP - Platelet Rich Plasma for Diminished Ovarian Reserve (DOR)
Phase-Based Progress Estimates
Effectiveness
Safety
Diminished Ovarian Reserve (DOR)+1 More
PRP - Platelet Rich Plasma - ProcedureEligibility
18 - 65
Female
What conditions do you have?
Select
Eligibility
18 - 65
Female
What conditions do you have?
Select
Study Summary
This trial will test whether Platelet Rich Plasma (PRP) can improve ovarian reserve in women with poor ovarian reserve. Women will be randomly assigned to treatment with either PRP or Platelet Poor Plasma (PPP).
Eligible Conditions
- Diminished Ovarian Reserve (DOR)
- Diminished Ovarian Reserve Due to Advanced Maternal Age
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 3 Secondary · Reporting Duration: 8 weeks
4 weeks
AMH
Antral Follicle Count
6 weeks
Embryo Transfer
Embryos Produced
8 weeks
Pregnancy
Trial Safety
Safety Progress
Trial Design
2 Treatment Groups
PRP group
1 of 2
PPP group
1 of 2
Experimental Treatment
Non-Treatment Group
90 Total Participants · 2 Treatment Groups
Primary Treatment: PRP - Platelet Rich Plasma · Has Placebo Group · N/A
PRP group
Procedure
Experimental Group · 1 Intervention: PRP - Platelet Rich Plasma · Intervention Types: ProcedurePPP group
Procedure
PlaceboComparator Group · 1 Intervention: PPP - Platelet Poor Plasma · Intervention Types: ProcedureTrial Logistics
Trial Timeline
Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 8 weeks
Who is running the clinical trial?
Center for Human ReproductionLead Sponsor
13 Previous Clinical Trials
1,083 Total Patients Enrolled
1 Trials studying Diminished Ovarian Reserve (DOR)
66 Patients Enrolled for Diminished Ovarian Reserve (DOR)
David H Barad, MDPrincipal InvestigatorCenter for Human Reproduction
1 Previous Clinical Trials
30 Total Patients Enrolled
Eligibility Criteria
Age 18 - 65 · Female Participants · 6 Total Inclusion Criteria
Mark “yes” if the following statements are true for you:About The Reviewer
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.
Who else is applying?
What state do they live in?
| New Jersey | 28.6% |
| New York | 28.6% |
| Utah | 14.3% |
| Other | 28.6% |
How old are they?
| 18 - 65 | 100.0% |
What site did they apply to?
| Center for Human Reproduction | 100.0% |
What portion of applicants met pre-screening criteria?
| Met criteria | 100.0% |
Popular Clinical Trials
Top Clinical Trials in Cities
Relevant Clinical Trials
Unbiased Results
We believe in providing patients with all the options.Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.Back to top
Conditions
Cancer Related
Treatments